| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Goldman Sachs analyst Scott Fidel initiates coverage on Ardent Health (NYSE:ARDT) with a Neutral rating and announces Price...
UBS analyst A.J. Rice initiates coverage on Ardent Health (NYSE:ARDT) with a Buy rating and announces Price Target of $17.
- SEC Filing
JP Morgan analyst Benjamin Rossi maintains Ardent Health (NYSE:ARDT) with a Neutral and lowers the price target from $18 to ...
Keybanc analyst Matthew Gillmor maintains Ardent Health (NYSE:ARDT) with a Overweight and lowers the price target from $24 t...